Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Influenza research Stories

2011-10-21 11:30:00

SWIFTWATER, Pa., Oct. 21, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the results of a new study evaluating the immunogenicity and safety of an investigational quadrivalent inactivated influenza vaccine (QIV) among adults 65 years of age and older. Currently licensed influenza vaccines target only three influenza virus strains anticipated to circulate in a given year. The data were presented at the 49th...

2011-10-21 11:00:00

BOSTON, Oct. 21, 2011 /PRNewswire/ -- MedImmune announced today it will present results of a Phase 3 pediatric clinical study of its investigational quadrivalent live attenuated influenza vaccine (Q/LAIV) compared with its trivalent (LAIV) formulation. The abstract will be presented at the 49th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 20 through October 23, 2011. The pivotal pediatric clinical study compared Q/LAIV to two trivalent...

2011-10-06 03:00:00

BLUE BELL, Pa., Oct. 6, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that the company is one of four firms recognized as "Life Sciences Company of the Year" in a tri-state competition sponsored by the Philadelphia Business Journal. In addition, Inovio's President and CEO, Dr. J. Joseph Kim, has been named "Life Sciences CEO of the Year," sharing this year's...

2011-10-03 11:00:00

A novel dry-powder formulation nasal flu vaccine for the H5N1 strain, GelVacâ“ž¢ Nasal Dry-Powder H5N1 Influenza, was proven to be safe in an early stage clinical trial. Other preliminary data is encouraging and support the development of larger scale clinical trials to confirm efficacy and show its distinct advantages in meeting the critical needs of pandemic preparedness. Alachua, Florida (PRWEB) October 03, 2011 Nanotherapeutics, Inc. announced the successful...

2011-09-29 10:00:00

LA JOLLA, Calif., Sept. 29, 2011 /PRNewswire/ -- Synthetic Genomics Vaccines, Inc. (SGVI), a privately held company focused on developing next generation vaccines using genomic sequencing and synthetic genomic technologies, announced today that Sammy J. Farah, Ph.D. has been appointed as president. Dr. Farah brings extensive vaccine expertise and over 15 years of scientific, business and executive management experience in the biotechnology industry to SGVI. "We are excited to have Sammy...

2011-09-27 03:00:00

BLUE BELL, Pa., Sept. 27, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Homeland Security (DHS) Science and Technology Directorate Plum Island Animal Disease Center. This collaboration will evaluate the efficacy of Inovio's...

2011-09-19 08:00:00

SWIFTWATER, Pa., Sept. 19, 2011 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that it began shipping the new Fluzone® Intradermal (Influenza Virus Vaccine) in the U.S. Sanofi Pasteur's other Fluzone vaccines for children, adults and seniors 65 years of age and older began shipping in July. Approximately 60 million doses of Fluzone influenza vaccines will have been shipped by the end of September. To view...

2011-09-06 03:00:00

BLUE BELL, Pa., Sept. 6, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has expanded its scientific advisory board with the appointment of two prominent leaders in the fields of vaccines and cancer immunotherapeutics. Joining Inovio's advisory board are Dr. Thomas S. Edgington, Emeritus Professor of the Scripps Research Institute and founder of several...

2011-08-23 18:02:09

New research from the Trudeau Institute may help to explain why live attenuated influenza vaccine (LAIV), commonly known as FluMist, elicits protection. The research is published in this month's issue of Vaccine. The journal article is entitled "Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses" and was authored by Trudeau Institute scientist Dr. Laura Haynes and her colleagues. "Our research specifically examines how the vaccine, which is commonly known...

2011-08-12 16:00:00

QUEBEC CITY, QC, Aug. 12, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced its operational and financial results for the second quarter ended June 30, 2011. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com. "During the second quarter, we made...